COVID-19

Pharma Courses 
PAGE Admission
  • PharmaTutor
    4 June 2020

    Corona virus disease-2019 (COVID-19) : The epidemic and the challenges

    ABOUT AUTHORS :
    Disha Chouhana*1, Dr. Rajesh Mujariya2
    1*Department of Pharmaceutical Chemistry, School of Pharmaceutical Science and Research , Balaghat, Madhya Pradesh, India
    2Department of Pharmaceutics,  School of Pharmaceutical Science and Research , Balaghat, Madhya Pradesh, India
    rajeshmujariya@gmail.com

    ABSTRACT :
    There is a new public health crises threatening the world with the emergence and spread of 2019 novel corona virus (2019-nCoV) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of corona virus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d.

  • 4 June 2020
    Five tips on how to live with novel coronavirus

    After seventy days of lockdown, the unlock 1.0 is put into action. Officially designated lockdown 5.0, from June 1, 2020, the economy and ordinary life are returning to normalcy in a controlled and phased manner. This is the beginning of a new normal. It is going to be a long haul. Experts and officials are suggesting that ‘we must learn to live with the virus’. With vaccine still months away, we need to live in a new normal. Speaking to India Science Wire, Prof. K Vijay Raghavan, Principal Scientific Advisor to the Government of India, gave five tips to ‘living with the virus’.

  • Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. ATR-002, an oral small molecule, has been proven in preclinical trials to block viral propagation of SARS-CoV-2 and to have an immunomodulatory effect leading to a decreased cytokine and chemokine release. This dual benefit makes the MEK-inhibitor ATR-002 particularly relevant for the treatment of COVID-19.

  • Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.

  • 30 May 2020
    COVID-19 : reminder of the risks of chloroquine and hydroxychloroquine

    EMA is reminding healthcare professionals to closely monitor patients with COVID-19 who are receiving chloroquine or hydroxychloroquine, given the serious side effects that can result from treatment with these medicines.

  • The development and availability of medicines and vaccines for all patients in the European Union, including those with COVID-19, is the number one priority for the European medicines regulatory network. EMA, together with EU Member States and the European Commission, has published a PDF iconplan outlining principles for how the network will ensure that core public and animal health regulatory activities, such as the authorisation, maintenance and supervision of human and veterinary medicines will continue to be carried out during the ongoing COVID-19 pandemic.

  • 31 May 2020
    Recruitment for Pharmacists (22 posts) due to COVID-19 outbreak - Government Jobs

  • Sun Pharmaceutical Industries Ltd and includes its subsidiaries and/or associate companies) has announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).

  • 28 May 2020
    Webinar on Telemedicine: The Covid-19 Pandemic Impact & Roadmap

Subscribe to COVID-19